Sex differences in CT-FFR of myocardial bridging with or without atherosclerosis: an AI-based quantitative study
Introduction
Myocardial bridging (MB), a common congenital coronary anomaly, is often considered a benign finding; however, growing evidence has established its association with serious cardiovascular events. Coronary computed tomography angiography (CCTA) has emerged as the primary non-invasive imaging modality for detecting MB. Nevertheless, it primarily provides anatomical information and offers limited ability to comprehensively evaluate the hemodynamic alterations induced by MB (1-3).
Although invasive fractional flow reserve (FFR) serves as the gold standard for functional ischemia assessment, its invasive nature limits its widespread clinical application (1,3). In recent years, the non-invasive computed tomography-derived FFR (FFRCT) technique has been developed and validated. This technology utilizes standard CCTA datasets without requiring additional scanning, thereby providing simultaneous anatomical and functional information. Multiple studies have validated the good concordance between FFRCT and invasive FFR in assessing hemodynamically significant coronary stenoses (4,5).
Nevertheless, research on the application of FFRCT specifically in MB patients remains scarce. Most existing FFRCT-related MB studies focused on validating its diagnostic performance against invasive FFR (6-8), or exploring the association between MB anatomical parameters and FFRCT values, with several limitations: first, nearly all studies analyzed MB patients as a homogeneous group without sex stratification, despite growing evidence of sex differences in coronary physiology (9); second, prior works either exclusively enrolled isolated MB patients or mixed cases with concomitant atherosclerosis (8,10), failing to clarify whether atherosclerosis modifies the sex-specific hemodynamic effect of MB itself; third, no study has systematically compared FFRCT profiles between isolated MB and MB combined with atherosclerosis across sexes.
To address these gaps, our study aims to leverage artificial intelligence (AI)-based CT-FFR to: (I) characterize sex-specific hemodynamic alterations in left anterior descending artery (LAD)-MB patients; (II) compare the magnitude of sex differences between isolated MB and MB + atherosclerosis subgroups; (III) identify sex-specific risk factors for hemodynamically significant MB. Our findings aim to provide evidence for sex-tailored risk stratification of MB. We present this article in accordance with the STROBE reporting checklist (available at https://qims.amegroups.com/article/view/10.21037/qims-2026-0713/rc).
Methods
Study population
This study retrospectively collected data from patients who underwent CCTA examination in the Department of Radiology, The Second Hospital of Hebei Medical University, between January 2019 and June 2022. The flow chart is shown in Figure 1. Based on strict inclusion and exclusion criteria, 404 patients were finally enrolled and divided into three groups: (I) MB group: 155 cases, median age 53 years, including 82 males and 73 females; (II) MB with atherosclerosis (MBLA) group: 145 cases, median age 55 years, including 83 males and 62 females; (III) control group: 104 cases, median age 54 years, including 25 males and 79 females. Inclusion criteria: (I) CCTA-confirmed LAD MB with depth ≥1.0 mm and presence of atherosclerotic plaque (calcified, non-calcified, or mixed) in the LAD, regardless of the degree of luminal stenosis; (II) good image quality in both systolic and diastolic phases without motion artifacts; (III) absence of MB or atherosclerotic plaques in other coronary arteries. Exclusion criteria: (I) complicated with cardiomyopathy and valvular disease; (II) presence of coronary artery aneurysm, coronary termination and origin anomalies; (III) poor CCTA image quality unable to meet diagnostic requirements; (IV) history of coronary artery bypass grafting or interventional therapy; (V) presence of cardiac pacemakers, artificial valves and other implants; (VI) presence of MB or atherosclerosis in non-LAD coronary arteries. Patients’ age, gender, body mass index (BMI), clinical symptoms (angina pectoris, atypical angina, chest tightness/pain, asymptomatic) and cardiovascular disease risk factors (hypertension, hyperlipidemia, diabetes, smoking) were collected.
Instrumentation and measurement methods
CCTA scanning protocol
A 256-slice Philips spiral CT scanner was used for examination. During scanning, patients were placed in supine position. Retrospective electrocardiogram (ECG)-gating technique was used. Patients underwent breathing training before scanning, with single end-expiratory breath-hold scanning performed for 5–7 seconds. The scanning range extended from 0.5 cm below the tracheal bifurcation to the cardiac diaphragm. The aortic threshold was set at 150 Hounsfield unit (HU), and intelligent tracking method was employed, with formal scanning initiating 6 seconds after reaching the threshold. Non-ionic contrast agent iohexol (350 mgI/mL) was injected using a dual-syringe high-pressure injector at a rate of 4–5 mL/s, with a dose of 0.8 mL/kg. Scanning parameters: tube voltage 80–120 kV, tube current 280–370 mAs/rotation, scan field of view 250 mm. Detector collimation 128×0.625, matrix 512×512, pitch 0.18, rotation time 330 ms. The optimal systolic (45%) and diastolic (75%) phases were reconstructed.
Image analysis
LAD-MB was diagnosed on CCTA as a segment of the LAD taking an intramyocardial course. Consistent with established criteria (11) and prognostic validation studies (6), MB was defined by a minimum myocardial thickness (depth) of ≥1.0 mm overlying the vessel during diastole. Patients were strictly stratified into an MB group (no atherosclerotic plaque in the LAD) and an MBLA group (presence of LAD plaque).
All CCTA raw data were imported into the post-processing workstation Philips EBW 6.0. Post-processing and analysis of systolic and diastolic images were performed using techniques including axial imaging, multi-planar reformation (MPR), volume rendering (VR) and curved planar reformation (CPR). Measurement of MB anatomical parameters was completed by two CCTA radiologists with more than 5 years of relevant experience, with each parameter measured three times and averaged (Table S1). The position of the MB (distance from the LAD ostium to the proximal end of the MB) and length (distance from the proximal to distal end of the MB) were measured on diastolic-phase CPR images. The depth of the MB (the maximum myocardial thickness overlying the coronary artery during diastole) was measured on vascular cross-sectional images (Figure 2) for subsequent statistical analysis. When the maximum myocardial thickness was ≤1 mm, it was uniformly recorded as 1 mm (11). The relevant calculation formulas are shown below (12-14):
Based on the presence or absence of calcification, plaques were classified into three types: calcified plaques, non-calcified plaques, and mixed plaques.
FFRCT analysis
An AI-based FFRCT analysis software (Shukun-FFRCT, Beijing, China) was employed to measure FFRCT values during both systolic and diastolic phases (Figure 2). This software utilizes an advanced deep learning AI platform for the non-invasive computation of FFRCT. FFR measurements were performed at three specific segments: the 10 mm segment proximal to the MB (FFR1), the MB segment with the most significant stenosis (or the mid-tunnel segment if no significant stenosis was present) (FFR2), and the segment 20–40 mm distal to the MB (FFR3). The ΔFFR was calculated as FFR1 − FFR3. Each FFRCT measurement was performed three times, and the average value was used for the final analysis. An abnormal FFRCT value was defined as ≤0.80 (3). Patients in both the MB group and the MBLA group were further subdivided based on sex into an FFRCT normal group (FFRCT >0.8) and an FFRCT abnormal group (FFRCT ≤0.8) to analyze the factors influencing FFRCT abnormalities across different sexes. The selection of these specific measurement locations (proximal 10 mm for flow acceleration; distal 20–40 mm for pressure recovery) aligns with established hemodynamic principles and prior literature (6).
Ethical statement
The study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. This study was approved by the Medical Ethics Committee of The Second Hospital of Hebei Medical University (approval No. W2023-R430). Informed consent was waived in this retrospective study.
Statistical analysis
Statistical analyses were conducted using SPSS software (version 25.0). Measurement data conforming to a normal distribution were expressed as mean ± standard deviation and compared using t-tests or one-way analysis of variance (ANOVA). Non-normally distributed measurement data were expressed as median and interquartile range [M (P25–P75)] and compared using the Mann-Whitney U test. Categorical data were presented as frequencies (percentages) and compared using the Chi-squared (χ2) test. Multifactorial analysis was performed using binary logistic regression to identify factors influencing FFRCT abnormalities. Variables for multivariable regression were selected via a hybrid approach: initial univariate screening (P<0.05) supplemented by a priori inclusion of clinically essential and literature-reported confounders, regardless of screening P values. A two-tailed P value of less than 0.05 (P<0.05) was considered statistically significant.
Results
Comparison of baseline characteristics and FFRCT values among groups
The comparison of baseline characteristics and FFRCT values among the MB group, MBLA group, and control group is presented in Table 1. Compared with the control group, the proportion of male patients was significantly higher in both the MB group and the MBLA group (P<0.05). Additionally, the smoking rate was higher in the MB group (P<0.05), while the incidence of angina pectoris was significantly higher in the MBLA group compared to the control group (P<0.05). No statistically significant differences were observed in other baseline indicators, including age, BMI, other risk factors, and clinical symptoms, between the case groups and the control group (P>0.05). Regarding hemodynamic parameters, both the MB group and the MBLA group showed significantly lower FFR1, FFR2, FFR3, and ΔFFR values compared to the control group during both systolic and diastolic phases (all P<0.01).
Table 1
| Variable | Subgroup | Control (n=104) | MB (n=155) | P1 | MBLA (n=145) | P2 |
|---|---|---|---|---|---|---|
| Basic information | Age (years) | 54.0 (45.0–59.0) | 53.0 (45.0–58.0) | 0.534 | 55.0 (49.0–59.5) | 0.288 |
| Male | 25 (24.0) | 82 (52.9) | <0.001 | 83 (57.2) | <0.001 | |
| BMI (kg/m2) | 24.9 (22.6–27.6) | 24.5 (22.9–26.1) | 0.287 | 24.8 (23.0–26.7) | 0.929 | |
| Risk factors | Hypertension | 32 (30.8) | 36 (23.2) | 0.176 | 43 (29.7) | 0.850 |
| Hyperlipidemia | 16 (15.4) | 16 (10.3) | 0.225 | 26 (17.9) | 0.597 | |
| Diabetes | 9 (8.7) | 15 (9.7) | 0.781 | 18 (12.4) | 0.347 | |
| Smoking | 6 (5.8) | 27 (17.4) | 0.006 | 15 (10.3) | 0.200 | |
| Clinical symptoms | Angina pectoris | 4 (3.8) | 13 (8.4) | 0.148 | 18 (12.4) | 0.019 |
| Atypical angina | 5 (4.8) | 10 (6.5) | 0.579 | 8 (5.5) | 0.804 | |
| Chest pain | 7 (6.7) | 14 (9.0) | 0.506 | 19 (13.1) | 0.105 | |
| Asymptomatic | 88 (84.6) | 118 (76.1) | 0.097 | 100 (69.0) | 0.005 | |
| Diastolic phase | FFR1 | 1.0 (1.0–1.0) | 1.0 (1.0–1.0) | 0.005 | 0.98 (0.94–1.0) | <0.001 |
| FFR2 | 1.0 (0.99–1.0) | 0.99 (0.97–1.0) | <0.001 | 0.96 (0.91–0.98) | <0.001 | |
| FFR3 | 0.97 (0.94–0.98) | 0.94 (0.88–0.97) | <0.001 | 0.89 (0.83–0.95) | <0.001 | |
| △FFR | 0.03 (0.01–0.06) | 0.06 (0.03–0.12) | <0.001 | 0.07 (0.03–0.11) | <0.001 | |
| Systolic phase | FFR1 | 1.0 (1.0–1.0) | 1.0 (1.0–1.0) | 0.024 | 0.99 (0.95–1.0) | <0.001 |
| FFR2 | 1.0 (0.99–1.0) | 0.99 (0.97–1.0) | <0.001 | 0.96 (0.90–0.98) | <0.001 | |
| FFR3 | 0.96 (0.93–0.98) | 0.93 (0.88–0.97) | <0.001 | 0.89 (0.82–0.93) | <0.001 | |
| △FFR | 0.04 (0.02–0.06) | 0.06 (0.03–0.11) | <0.001 | 0.07 (0.04–0.12) | <0.001 |
Data are presented as median (interquartile range) or n (%). FFR1, FFRCT value at 10 mm proximal to MB; FFR2, the FFRCT value at MB; FFR3, the FFRCT value at 20–40 mm from the far end of MB; △FFR, FFR1 − FFR3; P1, comparison between the MB group and the control group; P2, comparison between the MBLA group and the control group. BMI, body mass index; FFRCT, computed tomography-derived fractional flow reserve; MB, myocardial bridge; MBLA, myocardial bridge combined with left anterior descending artery atherosclerosis.
Sex-based differences in FFRCT values among MB patients
Comparisons of FFRCT values between sexes in patients with MB and MBLA are shown in Tables 2,3. During diastolic phase measurements in the MB group, female patients had significantly lower FFR3 values (P<0.05) and significantly higher ΔFFR values than males (P<0.05). No statistically significant differences were found in other FFRCT parameters between sexes (P>0.05).
Table 2
| MB | Subgroup | Male (n=82) | Female (n=73) | P |
|---|---|---|---|---|
| Diastolic phase FFRCT | FFR1 | 1.00 (1.00–1.00) | 1.00 (1.00–1.00) | 0.997 |
| FFR2 | 0.99 (0.98–1.00) | 0.99 (0.97–1.00) | 0.304 | |
| FFR3 | 0.95 (0.90–1.00) | 0.92 (0.87–0.96) | 0.006 | |
| △FFR | 0.05 (0.02–0.10) | 0.08 (0.04–0.13) | 0.004 | |
| Systolic phase FFRCT | FFR1 | 1.00 (1.00–1.00) | 1.00 (1.00–1.00) | 0.363 |
| FFR2 | 0.99 (0.97–1.00) | 0.99 (0.98–1.00) | 0.929 | |
| FFR3 | 0.94 (0.89–0.97) | 0.92 (0.86–0.97) | 0.120 | |
| △FFR | 0.06 (0.03–0.10) | 0.08 (0.03–0.12) | 0.080 |
Data are presented as median (interquartile range). FFR1, FFRCT value at 10 mm proximal to MB; FFR2, the FFRCT value at MB; FFR3, the FFRCT value at 20–40 mm from the far end of MB; △FFR, FFR1 − FFR3. FFRCT, computed tomography-derived fractional flow reserve; MB, myocardial bridge.
Table 3
| MBLA | Subgroup | Male (n=83) | Female (n=62) | P |
|---|---|---|---|---|
| Diastolic phase FFRCT | FFR1 | 0.98 (0.92–1.00) | 0.98 (0.96–1.00) | 0.819 |
| FFR2 | 0.95 (0.87–0.98) | 0.96 (0.93–0.98) | 0.489 | |
| FFR3 | 0.89 (0.82–0.94) | 0.91 (0.86–0.95) | 0.617 | |
| △FFR | 0.06 (0.03–0.11) | 0.07 (0.03–0.10) | 0.641 | |
| Systolic phase FFRCT | FFR1 | 0.99 (0.95–1.00) | 0.98 (0.95–1.00) | 0.322 |
| FFR2 | 0.95 (0.86–0.98) | 0.96 (0.93–0.98) | 0.329 | |
| FFR3 | 0.87 (0.81–0.94) | 0.90 (0.85–0.93) | 0.469 | |
| △FFR | 0.08 (0.03–0.14) | 0.07 (0.04–0.10) | 0.430 |
Data are presented as 95% (CI). FFR1, FFRCT value at 10 mm proximal to MB; FFR2, the FFRCT value at MB; FFR3, the FFRCT value at 20–40 mm from the far end of MB; △FFR, FFR1 − FFR3. CI, confidence interval; FFRCT, computed tomography-derived fractional flow reserve; MBLA, myocardial bridge combined with left anterior descending artery atherosclerosis.
Analysis of factors influencing FFRCT abnormalities in male MB patients
MB patients were categorized into normal and abnormal FFRCT groups based on their FFRCT values. The comparison of baseline characteristics between these two groups is presented in Table 4. Except for a significant difference in MB length between the two groups (P<0.05), no statistically significant differences were found in age, BMI, cardiovascular risk factors, or clinical symptoms (P>0.05). Binary logistic regression analysis incorporating these variables and other clinically relevant or literature-reported factors (Table 5) revealed that MB length was an independent risk factor for FFRCT abnormalities [odds ratio (OR) =1.053, 95% confidence interval (CI): 1.004–1.104; P=0.033]. This indicates that for every 1 mm increase in MB length, the risk of FFRCT abnormality increases by 5.3% in male patients.
Table 4
| Variable | Subgroup | FFRCT ≤0.8 (n=34) | FFRCT >0.8 (n=48) | P |
|---|---|---|---|---|
| Basic information | Age (years) | 51.50 (40.50–54.50) | 51.00 (43.00–57.00) | 0.351 |
| BMI (kg/m2) | 24.54±2.51 | 24.88 (23.06–37.32) | 0.457 | |
| Risk factors | Hypertension | 7 (20.6) | 12 (25.0) | 0.641 |
| Hyperlipidemia | 2 (5.9) | 4 (8.3) | >0.99 | |
| Diabetes | 3 (8.8) | 6 (12.5) | 0.868 | |
| Smoking | 9 (26.5) | 13 (27.1) | 0.951 | |
| Clinical symptoms | Angina pectoris | 10 (29.4) | 6 (12.5) | 0.057 |
| Atypical angina | 0 (0.0) | 1 (2.1) | >0.99 | |
| Chest pain | 22 (64.7) | 14 (29.2) | 0.675 | |
| Asymptomatic | 10 (29.4) | 19 (39.6) | 0.343 | |
| MB anatomy | Length (mm) | 26.7 (19.8–33.9) | 20.7 (14.4–32.7) | 0.028 |
| Depth (mm) | 1.80 (1.00–3.53) | 1.95 (1.00–3.40) | 0.958 | |
| Location (mm) | 30.7 (28.83–48.03) | 36.64±11.98 | 0.884 | |
| Systolic compression index | 0.11 (0.00–0.17) | 0.08 (0.06–0.14) | 0.774 | |
| MBMI | 42.35 (27.70–119.36) | 38.44 (18.28–86.02) | 0.255 | |
| MB stenosis in diastole | 0.36±0.15 | 0.32±0.12 | 0.394 | |
| MB stenosis in systole | 0.35±0.19 | 0.34±0.14 | 0.825 |
Data are presented as median (interquartile range), n (%), or mean ± standard deviation. BMI, body mass index; FFRCT, computed tomography-derived fractional flow reserve; MB, myocardial bridge; MBMI, MB muscle index.
Table 5
| Variable | Subgroup | FFRCT ≤0.8 (n=37) | FFRCT >0.8 (n=36) | P |
|---|---|---|---|---|
| Basic information | Age (years) | 53.24±9.29 | 55.97±10.03 | 0.137 |
| BMI (kg/m2) | 24.02 (22.05–26.19) | 24.13 (22.93–25.68) | 0.873 | |
| Risk factors | Hypertension | 8 (21.6) | 9 (25.0) | 0.733 |
| Hyperlipidemia | 7 (18.9) | 3 (8.3) | 0.330 | |
| Diabetes | 3 (8.1) | 3 (8.3) | >0.99 | |
| Smoking | 3 (8.1) | 2 (5.6) | >0.99 | |
| Clinical symptoms | Angina pectoris | 8 (21.6) | 4 (11.1) | 0.226 |
| Atypical angina | 4 (10.8) | 5 (13.9) | 0.965 | |
| Chest pain | 12 (32.4) | 10 (27.8) | 0.665 | |
| Asymptomatic | 13 (35.1) | 17 (47.2) | 0.294 | |
| MB anatomy | Length (mm) | 23.90 (17.85–39.65) | 15.55 (12.10–24.65) | 0.001 |
| Depth (mm) | 1.00 (1.00–2.55) | 1.00 (1.00–2.08) | 0.266 | |
| Location (mm) | 33.70 (26.65–43.00) | 40.2±13.12 | 0.141 | |
| Systolic compression index | 0.10 (0.00–0.15) | 0.08 (0.05–0.16) | 0.903 | |
| MBMI | 33.46 (20.80–94.04) | 22.14 (12.98–33.54) | 0.004 | |
| MB stenosis in diastole | 0.31±0.12 | 0.27±0.12 | 0.102 | |
| MB stenosis in systole | 0.34±0.13 | 0.25 (0.16–0.37) | 0.024 |
Data are presented as median (interquartile range), n (%), or mean ± standard deviation. BMI, body mass index; FFRCT, computed tomography-derived fractional flow reserve; MB, myocardial bridge; MBMI, MB muscle index.
Analysis of factors influencing FFRCT abnormalities in female MB patients
The comparison of baseline characteristics between female MB patients with normal and abnormal FFRCT values is shown in Table 5. While no significant differences were observed in age, BMI, risk factors, or clinical symptoms between the two groups (P>0.05), three parameters showed statistically significant differences: MB length, muscle contraction index, and MB systolic stenosis rate (P<0.05). Binary logistic regression analysis that included these variables and other clinically significant factors (Table 6) demonstrated that MB length was an independent risk factor for FFRCT abnormalities in female patients (OR =1.113, 95% CI: 1.024–1.209; P=0.011). This corresponds to an 11.3% increase in FFRCT abnormality risk for every 1 mm increase in MB length among female patients.
Table 6
| Variable | Univariate | Multivariate | |||
|---|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | ||
| Male | |||||
| Angina pectoris | 0.343 (0.111–1.061) | 0.057 | 0.351 (0.109–1.130) | 0.079 | |
| Length (mm) | 1.053 (1.006–1.102) | 0.028 | 1.053 (1.004–1.104) | 0.033 | |
| Female | |||||
| Age (years) | 0.970 (0.924–1.019) | 0.137 | 0.962 (0.911–1.015) | 0.157 | |
| Length (mm) | 1.078 (1.025–1.133) | 0.001 | 1.113 (1.024–1.209) | 0.011 | |
| Location (mm) | 0.971 (0.933–1.010) | 0.141 | 0.975 (0.930–1.022) | 0.290 | |
| MBMI | 1.011 (0.999–1.023) | 0.004 | 0.987 (0.967–1.007) | 0.190 | |
| MB stenosis in diastole | 20.570 (0.372–1,137.556) | 0.102 | 0.126 (0.000–248.054) | 0.593 | |
| MB stenosis in systole | 38.744 (0.992–1,512.925) | 0.024 | 7.832 (0.007–8,853.104) | 0.566 | |
FFRCT, computed tomography-derived fractional flow reserve; MB, myocardial bridge; MBMI, MB muscle index.
Comparison of FFRCT values between cardiac systolic and diastolic phases
Intra-group comparisons of FFRCT values between systolic and diastolic phases in the MB group, MBLA group, and control group are shown in Figure 3. No statistically significant differences in FFRCT values were observed between systolic and diastolic phases in any of the three groups (P>0.05).
Discussion
This study, through CT-based AI quantitative analysis, innovatively and systematically reveals the significant role of sex differences in the FFRCT assessment of patients with MB of the LAD. The results not only confirm the substantial impact of MB on coronary hemodynamics but, more importantly, uncover sex-specific manifestations under different pathological conditions-namely, isolated MB versus MBLA. This provides a new theoretical foundation for the precise diagnosis and treatment of MB.
The most critical finding of this study is the first systematic identification of sex-based differences in CT-FFR assessment of LAD-MB, which expands on prior literature in three aspects: first, compared with Zhou et al. (6) and Zhang et al. (7) that primarily validated the feasibility of FFRCT in MB evaluation, we for the first time demonstrated that sex is an effect modifier of MB-induced hemodynamic impairment: isolated MB led to significantly lower distal FFRCT and larger trans-bridge pressure drop in females, a phenomenon unreported in previous MB functional studies. Second, distinct from Sun et al. (8) that mixed isolated MB and MBLA in analysis, we further found that this sex difference was completely masked when MB coexisted with atherosclerosis, indicating that plaque-related fixed stenosis overrides the dynamic hemodynamic effect of MB itself—a finding that explains the inconsistent sex-related results in prior MB studies with heterogeneous populations. Third, our sex-stratified regression analysis revealed that MB length exerted a significantly stronger effect on FFRCT abnormality risk in females (11.3% per mm) than in males (5.3% per mm), providing the first quantitative evidence for female-specific vulnerability to MB anatomical variations. This finding aligns with prior evidence that atherosclerotic stenosis dominates hemodynamic impairment (7), and further clarifies for the first time that this dominance eliminates the sex disparities observed in isolated MB.
The sex differences in the hemodynamic effects of MB may stem from multiple interacting factors. Firstly, hormonal variations may lead to differences in vascular reactivity; the protective effect of estrogen on vascular endothelial function could make females more sensitive to hemodynamic changes induced by MB (9). Secondly, sex-based differences in coronary microcirculation may affect the compensatory capacity for flow disturbances caused by MB (15). Additionally, the finding that MB length has a greater impact on females (an 11.3% increase in risk per mm) suggests that female coronary arteries may have lower tolerance for anatomical changes.
The results indicate that when MB is accompanied by atherosclerosis, sex differences are no longer significant, likely because atherosclerosis itself becomes the predominant hemodynamic influencing factor. Consistent with our multivariable analysis in this cohort, the loss of significance for MB anatomy after adjusting for plaque characteristics underscores a pathophysiological hierarchy: fixed atherosclerotic stenosis overrides the dynamic compression effect of the bridge. This highlights the importance of distinguishing between isolated MB and MBLA in clinical assessment. As highlighted by Fogante et al. (16), combining CCTA and stress computed tomography perfusion (CTP) provides a comprehensive assessment. Although FFRCT quantifies dynamic compression, CTP captures myocardial perfusion, which may be particularly relevant in atherosclerotic cohorts where MB anatomy is overshadowed by plaque burden. Notably, while atherosclerosis typically spares the tunneled segment, preferentially affecting the proximal LAD, our definition of “MB with atherosclerosis” included any plaque within the LAD. Future studies should investigate how plaque location relative to the MB influences hemodynamics.
The AI-based FFRCT analysis technology used in this study offers significant methodological advantages. Recent prospective comparisons of various CT-FFR interpretation methods have validated the robustness and diagnostic accuracy of such computational platforms (17). While traditional FFR measurement is invasive, the non-invasive FFRCT technique employed here maintains diagnostic accuracy while avoiding the risks associated with invasive procedures. By systematically measuring FFRCT values at different segments (proximal, within, and distal to the MB), this study provides a comprehensive assessment of the impact of MB on coronary blood flow. Furthermore, dual-phase analysis ensured result reliability, and the finding of no significant difference between systolic and diastolic FFRCT values further confirms the persistent effect of MB.
Compared to the study by Zhou et al. (6), which primarily validated the value of FFRCT in MB assessment, our research further reveals the influence of sex factors. Previous studies (7,8) mostly focused on the anatomical characteristics of MB or isolated functional assessments. This study innovatively incorporates sex factors into the analytical framework, offering a new perspective for understanding the heterogeneity of MB. The sex differences identified particularly in the isolated MB group provide important clues for understanding the diverse clinical manifestations of MB.
The findings of this study hold significant clinical translational value. Firstly, increased attention should be given to female MB patients, especially those with greater MB length, who may require closer follow-up. Secondly, clinical assessment of MB should distinguish between cases with and without concomitant atherosclerosis, as management strategies may differ. Additionally, FFRCT, as a non-invasive examination tool, can serve as an important method for the long-term follow-up of MB patients.
Summary of novel contributions
This study provides three novel insights into MB pathophysiology and management: (I) it is the first to report sex disparities in FFRCT profiles of LAD-MB, challenging the traditional perception of MB as a “sex-neutral” condition; (II) it clarifies that atherosclerosis co-existence eliminates MB-related sex differences, highlighting the necessity of stratifying MB patients by plaque burden in clinical assessment; (III) it identifies MB length as a sex-specific risk factor for hemodynamic impairment, supporting more aggressive risk stratification for females with long MB. These hemodynamic alterations carry direct clinical implications.
The observed FFRCT differences are clinically meaningful. Since an FFRCT ≤0.80 signifies hemodynamically significant ischemia, the lower distal FFRCT in females with isolated MB indicates a greater ischemic burden. This supports closer surveillance in this subgroup. While our cross-sectional design cannot establish causality for clinical outcomes, prior studies associate ischemic FFRCT in MB with adverse events (18-20). Future prospective studies are needed to confirm if these sex-specific FFRCT patterns predict long-term risk.
Some limitations existed in our study. First, the retrospective design inevitably introduced selection bias regarding sex distribution (MB and MBLA groups: 52.9–57.2% male vs. control: 24%). Although this aligns with clinical epidemiology-where females more frequently undergo CCTA for chest pain but often have normal findings-we performed multivariable adjustment and interaction analysis. While the interaction term did not reach statistical significance (P=0.459), likely due to limited power, the consistent trend of higher ORs in females supports our findings. Second, the single-centre design, modest cohort size, and inclusion of only Chinese patients may limit generalizability. Third, the limited number of events within specific subgroups resulted in extremely wide CIs for certain variables (systolic MB stenosis in females: OR =7.832, 95% CI: 0.007–8,853.104), reflecting statistical instability. Fourth, we did not account for the potential impact of nitroglycerin administration, which has been shown to significantly alter machine-learning FFRCT values in CCTA (21). Future prospective studies should consider standardizing vasodilator protocols to control for this variable.
Clinical Implications and management recommendations
Based on our findings, we propose sex-specific strategies for managing LAD-MB: risk stratification: due to the 11.3% increased risk per mm, women with isolated MB >20 mm warrant regular monitoring, including clinical reassessment and consideration of repeat FFRCT within 1–2 years. Diagnostic optimization: for females with angina but non-obstructive CCTA plaques, utilize FFRCT to differentiate ischemia driven by dynamic compression (MB) versus fixed stenosis (atherosclerosis). Therapeutic tailoring: symptomatic females with isolated MB and FFRCT ≤0.80 should receive beta-blockers or referral for surgical unroofing. Conversely, management for MBLA should align with standard coronary artery disease (CAD) guidelines (statins/anti-platelets), focusing on plaque rather than the bridge.
Conclusions
In conclusion, utilizing AI-based CT-FFR technology, this study demonstrates that sex significantly influences the hemodynamic assessment of LAD-MB, particularly in isolated MB. While atherosclerosis appears to mask these sex differences, MB length emerged as a potent risk factor, especially in females. These findings provide preliminary evidence to inform risk stratification and long-term management. Future integration with modalities like stress CTP may offer a more comprehensive assessment of MB.
Acknowledgments
We would like to thank the Department of Radiology at The Second Hospital of Hebei Medical University for their support and assistance during data collection. Additionally, we acknowledge that the data collection for this study was completed during the corresponding author’s doctoral studies at The Second Hospital of Hebei Medical University.
Footnote
Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at https://qims.amegroups.com/article/view/10.21037/qims-2026-0713/rc
Data Sharing Statement: Available at https://qims.amegroups.com/article/view/10.21037/qims-2026-0713/dss
Funding: This study was supported by
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://qims.amegroups.com/article/view/10.21037/qims-2026-0713/coif). The authors have no conflicts of interest to declare.
Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. This study was approved by the Medical Ethics Committee of The Second Hospital of Hebei Medical University (approval No. W2023-R430). Informed consent was waived in this retrospective study.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References
- Maeda K, Schnittger I, Murphy DJ, Tremmel JA, Boyd JH, Peng L, Okada K, Pargaonkar VS, Hanley FL, Mitchell RS, Rogers IS. Surgical unroofing of hemodynamically significant myocardial bridges in a pediatric population. J Thorac Cardiovasc Surg 2018;156:1618-26. [Crossref] [PubMed]
- Möhlenkamp S, Hort W, Ge J, Erbel R. Update on myocardial bridging. Circulation 2002;106:2616-22. [Crossref] [PubMed]
- Tarantini G, Barioli A, Nai Fovino L, Fraccaro C, Masiero G, Iliceto S, Napodano M. Unmasking Myocardial Bridge-Related Ischemia by Intracoronary Functional Evaluation. Circ Cardiovasc Interv 2018;11:e006247. [Crossref] [PubMed]
- Fairbairn TA, Nieman K, Akasaka T, Nørgaard BL, Berman DS, Raff G, et al. Real-world clinical utility and impact on clinical decision-making of coronary computed tomography angiography-derived fractional flow reserve: lessons from the ADVANCE Registry. Eur Heart J 2018;39:3701-11. [Crossref] [PubMed]
- Kurata A, Coenen A, Lubbers MM, Nieman K, Kido T, Kido T, Yamashita N, Watanabe K, Krestin GP, Mochizuki T. The effect of blood pressure on non-invasive fractional flow reserve derived from coronary computed tomography angiography. Eur Radiol 2017;27:1416-23. [Crossref] [PubMed]
- Zhou F, Tang CX, Schoepf UJ, Tesche C, Rollins JD, Liu H, Zhou CS, Yan J, Lu MJ, Lu GM, Ni QQ, Zhang LJ. Machine Learning Using CT-FFR Predicts Proximal Atherosclerotic Plaque Formation Associated With LAD Myocardial Bridging. JACC Cardiovasc Imaging 2019;12:1591-3. [Crossref] [PubMed]
- Zhang D, Tian X, Li MY, Zheng WS, Yu Y, Zhang HW, Pan T, Gao BL, Li CY. Quantitative computed tomography angiography evaluation of the coronary fractional flow reserve in patients with left anterior descending artery myocardial bridging. Clin Physiol Funct Imaging 2024;44:251-9. [Crossref] [PubMed]
- Sun Q, Zhang J, Wang W, Qi Y, Lyu J, Zhang X, Li T, Lou X. Predictors of discordance between CT-derived fractional flow reserve (CT-FFR) and △CT-FFR in deep coronary myocardial bridging. Clin Imaging 2024;114:110264. [Crossref] [PubMed]
- Yu Y, Kou J, Guo F, Zhang D, Pan T, Chen Y, Bao W, Sun Y, Zhang H, Li C. Prognostic value of CT-derived fractional flow reserve and fat attenuation index in patients with suspected coronary artery disease: a sex-disaggregated analyses. BMC Cardiovasc Disord 2023;23:612. [Crossref] [PubMed]
- Zhou F, Tang CX, Schoepf UJ, Tesche C, Bauer MJ, Jacobs BE, Zhou CS, Yan J, Lu MJ, Lu GM, Zhang LJ. Fractional flow reserve derived from CCTA may have a prognostic role in myocardial bridging. Eur Radiol 2019;29:3017-26. [Crossref] [PubMed]
- Yu M, Zhang Y, Li Y, Li M, Li W, Zhang J. Assessment of Myocardial Bridge by Cardiac CT: Intracoronary Transluminal Attenuation Gradient Derived from Diastolic Phase Predicts Systolic Compression. Korean J Radiol 2017;18:655-63. [Crossref] [PubMed]
- Liu SH, Yang Q, Chen JH, Wang XM, Wang M, Liu C. Myocardial bridging on dual-source computed tomography: degree of systolic compression of mural coronary artery correlating with length and depth of the myocardial bridge. Clin Imaging 2010;34:83-8. [Crossref] [PubMed]
- Konen E, Goitein O, Sternik L, Eshet Y, Shemesh J, Di Segni E. The prevalence and anatomical patterns of intramuscular coronary arteries: a coronary computed tomography angiographic study. J Am Coll Cardiol 2007;49:587-93. [Crossref] [PubMed]
- Ishikawa Y, Akasaka Y, Suzuki K, Fujiwara M, Ogawa T, Yamazaki K, et al. Anatomic properties of myocardial bridge predisposing to myocardial infarction. Circulation 2009;120:376-83. [Crossref] [PubMed]
- Shabbir A, Rathod KS, Khambata RS, Ahluwalia A. Sex Differences in the Inflammatory Response: Pharmacological Opportunities for Therapeutics for Coronary Artery Disease. Annu Rev Pharmacol Toxicol 2021;61:333-59. [Crossref] [PubMed]
- Fogante M, Pirani PE, Cela F, Paolini E, Balardi L, Schicchi N. Combined CCTA and Stress CTP for Anatomical and Functional Assessment of Myocardial Bridges. J Imaging 2025;11:324. [Crossref] [PubMed]
- Xu K, Yang L, Zhang J, Huang W, Hu Y, Leng X, Liu Y, Liu X, Jin H, Tang Y, Wang J, Guo Y, Ye C, Zhang J, Xiang J, Tang L, Du C. Prospective comparisons of three interpretation methods of fractional flow reserve derived from coronary computed tomography angiography. Quant Imaging Med Surg 2025;15:2146-61. [Crossref] [PubMed]
- Cheng SH, Ni J, Liu J, Huang F, Wang PJ. The role of Artificial intelligent-based FFR(CT) in assessing the hemodynamic relevance of deep myocardial bridge of the left anterior descending coronary artery. Zhonghua Yi Xue Za Zhi 2021;101:464-9. [Crossref] [PubMed]
- Sternheim D, Power DA, Samtani R, Kini A, Fuster V, Sharma S. Myocardial Bridging: Diagnosis, Functional Assessment, and Management: JACC State-of-the-Art Review. J Am Coll Cardiol 2021;78:2196-212. [Crossref] [PubMed]
- Iyer KV, Hieger RJ, Rajput R, Raymer KL, Ganesan AP, Khoukaz S, Roukoz B, Mikhail B, Kim JP, Oke VV. Myocardial Bridging and Cardiac Arrest. JACC Case Rep 2026;31:106736. [Crossref] [PubMed]
- Zhou Y, Zhao N, An Y, Ma W, Han L, Song L, Yang W, Gao Y, Lu B. Impact of nitroglycerin on machine-learning fractional flow reserve in coronary computed tomography (CT)-angiography. Quant Imaging Med Surg 2024;14:6856-68. [Crossref] [PubMed]

